免疫タンパク質市場：製品、用途、エンドユーザー別-2025～2030年の世界予測

免疫タンパク質市場は、2023年に196億4,000万米ドルと評価され、2024年には215億4,000万米ドルに達すると予測され、CAGR 10.16％で成長し、2030年には386億7,000万米ドルに達すると予測されています。

免疫タンパク質は、免疫グロブリン、サイトカイン、補体タンパク質など、身体の免疫反応に関与するタンパク質を指します。免疫タンパク質の市場範囲は、診断、治療、研究用途に及びます。自己免疫疾患、アレルギー、感染症、がんの診断や治療に重要な役割を果たすことから、必要性が高まっています。診断学では、免疫系機能を評価するバイオマーカーとしての役割を果たし、治療学では、免疫タンパク質由来のモノクローナル抗体は標的治療において極めて重要です。最終用途には、臨床検査機関、病院、研究機関などが含まれます。市場成長の原動力は、バイオテクノロジーとゲノミクスの進歩、慢性疾患の増加、個別化医療の需要です。主要成長機会は、免疫タンパク質を活用した新規治療法やポイントオブケア診断ツールの開発にあります。しかし、研究開発コストの高さ、厳しい規制の枠組み、拡大性や再現性の問題といった課題が、市場の進展を妨げています。また、検査手法の標準化が限定的であることも、市場の信頼性と信用性に影響を及ぼす可能性があります。新たな機会を捉えるために、利害関係者はより安全で効果的な免疫タンパク質によるソリューションを革新するための共同研究に投資し、ビッグデータを活用するためのバイオインフォマティクスの技術能力を強化すべきです。神経変性疾患など、未開拓の用途セグメントへの多角化は、未開拓の成長の可能性を提供する可能性があります。さらに、新興市場へのアクセスを拡大することで、医療インフラが発展しつつある地域での需要を喚起することができます。技術革新は、イムノアッセイの特異性と感度の向上、低資源環境向けのコスト効率の高い携帯型診断キットの開発に集中する可能性があります。市場競争は激しく、製品パイプラインと市場シェアを強化するための戦略的提携や買収が目立つ。継続的なイノベーションと戦略的適応を通じて現在の課題に取り組むことで、企業は免疫タンパク質のポテンシャルを最大限に活用し、ダイナミックな医療環境における地位を確固たるものにすることができます。

市場力学：急速に進化する免疫タンパク質市場の主要市場洞察を公開

免疫タンパク質市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症と慢性疾患の罹患率と有病率の増加
  • 世界の高齢者の増加と診断検査の増加
  • 迅速かつ正確な疾病診断への嗜好
• 市場抑制要因
  • 免疫タンパク質検査はルーチンの微生物学的検査と比較してコストが高い
• 市場機会
  • 免疫診断機器の技術的進歩
  • 重篤な疾患に対する治療を発見するための効果的な研究開発努力
• 市場課題
  • 代替検査アプローチの利用可能性

ポーターのファイブフォース：免疫タンパク質市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：免疫タンパク質市場における外部からの影響の把握

外部マクロ環境要因は、免疫タンパク質市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：免疫タンパク質市場における競合情勢の把握

免疫タンパク質市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：免疫タンパク質市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、免疫タンパク質市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：免疫タンパク質市場における成功への道筋を描く

免疫タンパク質市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症と慢性疾患の発生率と有病率の増加
    • 世界中で高齢者が増加し、診断検査も増加
    • 迅速かつ正確な病気の診断を優先
  • 抑制要因
    • 免疫タンパク質検査は、通常の微生物検査に比べて費用がかかる
  • 機会
    • 免疫診断機器の技術的進歩
    • 重篤な疾患に対する治療法を発見するための効果的な研究開発の取り組み
  • 課題
    • 代替テストアプローチの利用可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 免疫タンパク質市場：製品別

• イントロダクション
• C3
• C4
• 遊離軽鎖
• ハプトグロビン
• 免疫グロブリンA
• 特異的IgE
• 総IgE
• IgG
• IgM
• 免疫固定法
• プレアルブミン
• タンパク質電気泳動

第7章 免疫タンパク質市場：用途別

• イントロダクション
• アレルギー検査
• 自己免疫検査
• 感染症検査
• 腫瘍学と内分泌学検査

第8章 免疫タンパク質市場：エンドユーザー別

• イントロダクション
• 病院・クリニック

第9章 南北アメリカの免疫タンパク質市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の免疫タンパク質市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの免疫タンパク質市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amgen Inc.
• Celltrion Healthcare Co., Ltd.
• Eli Lilly and Company
• Entera Health, Inc.
• Genentech, Inc. by F. Hoffmann-La Roche Ltd
• Glaxosmithkline PLC
• Merck KGaA
• Neurobiologix, Inc.
• Novartis AG
• Pfizer Inc.
• Progurt Inc.
• Samsung Biologics by Samsung Electronics Co., Ltd.
• SERO AS
• TECHNOPATH Distribution Ltd. by Diploma PLC
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. IMMUNOPROTEIN MARKET RESEARCH PROCESS
• FIGURE 2. IMMUNOPROTEIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IMMUNOPROTEIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES IMMUNOPROTEIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES IMMUNOPROTEIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. IMMUNOPROTEIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. IMMUNOPROTEIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IMMUNOPROTEIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IMMUNOPROTEIN MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IMMUNOPROTEIN MARKET DYNAMICS
• TABLE 7. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY C3, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY C4, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY FREE LIGHT CHAINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY HAPTOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY IGA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY IGE SPECIFIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY IGE TOTAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY IGG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY IGM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY IMMUNOFIXATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY PREALBUMIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY PROTEIN ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY ALLERGY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY AUTOIMMUNE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY ONCOLOGY & ENDOCRINOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL IMMUNOPROTEIN MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. CANADA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. CANADA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES IMMUNOPROTEIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. CHINA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. CHINA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. CHINA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. INDIA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. INDIA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. INDIA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. JAPAN IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. MALAYSIA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. PHILIPPINES IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. SINGAPORE IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. SOUTH KOREA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. TAIWAN IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. THAILAND IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. VIETNAM IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA IMMUNOPROTEIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. DENMARK IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. EGYPT IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. FINLAND IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. FRANCE IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. GERMANY IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. ISRAEL IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. ITALY IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. ITALY IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. ITALY IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NETHERLANDS IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. NIGERIA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. NORWAY IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. POLAND IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. POLAND IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. POLAND IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. QATAR IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. QATAR IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. QATAR IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. RUSSIA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SAUDI ARABIA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH AFRICA IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SPAIN IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. SWEDEN IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. SWITZERLAND IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. TURKEY IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. UNITED ARAB EMIRATES IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM IMMUNOPROTEIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM IMMUNOPROTEIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM IMMUNOPROTEIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. IMMUNOPROTEIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 155. IMMUNOPROTEIN MARKET, FPNV POSITIONING MATRIX, 2023

The Immunoprotein Market was valued at USD 19.64 billion in 2023, expected to reach USD 21.54 billion in 2024, and is projected to grow at a CAGR of 10.16%, to USD 38.67 billion by 2030.

Immunoprotein refers to proteins involved in the body's immune response, including immunoglobulins, cytokines, and complement proteins. The market scope for immunoproteins extends across diagnostics, therapeutics, and research applications. Necessity arises from their critical role in diagnosing and treating autoimmune diseases, allergies, infections, and cancer. In diagnostics, they serve as biomarkers to assess immune system function, while in therapeutics, monoclonal antibodies derived from immunoproteins are pivotal in targeted therapies. The end-use scope includes clinical laboratories, hospitals, and research institutions. Market growth is driven by advances in biotechnology and genomics, the increasing prevalence of chronic diseases, and demand for personalized medicine. Key growth opportunities lie in the development of novel therapies and point-of-care diagnostic tools leveraging immunoproteins. However, challenges such as high R&D costs, stringent regulatory frameworks, and issues of scalability and reproducibility hinder progress in the market. Limited standardization in testing methodologies can also affect the market's credibility and reliability. To seize emerging opportunities, stakeholders should invest in collaborative research to innovate safer, more effective immunoprotein-based solutions and enhance technological capabilities in bioinformatics to harness big data. Diversification into underexplored applications, such as neurodegenerative diseases, could offer untapped potential for growth. Additionally, expanding access to emerging markets can fuel demand where healthcare infrastructure is evolving. Innovation could focus on improving the specificity and sensitivity of immunoassays and developing cost-effective, portable diagnostic kits for lower-resource settings. The market nature is competitive, marked by strategic partnerships and acquisitions to bolster product pipelines and market share. By addressing current challenges through continuous innovation and strategic adaptation, businesses can leverage immunoproteins' full potential, solidifying their position in a dynamic healthcare landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunoprotein Market

The Immunoprotein Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growth in incidence & prevalence of infectious and chronic diseases
  • Rising geriatric population across world and increase in diagnostic tests
  • Preferences for quick and accurate disease diagnosis
• Market Restraints
  • Immunoprotein tests are costly as compared to routine microbiology assays
• Market Opportunities
  • Technological advancements in immunodiagnostic instruments
  • Effective R&D efforts to discover therapeutics against critical disease
• Market Challenges
  • Availability of alternative testing approaches

Porter's Five Forces: A Strategic Tool for Navigating the Immunoprotein Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunoprotein Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunoprotein Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunoprotein Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunoprotein Market

A detailed market share analysis in the Immunoprotein Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunoprotein Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunoprotein Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunoprotein Market

A strategic analysis of the Immunoprotein Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunoprotein Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Celltrion Healthcare Co., Ltd., Eli Lilly and Company, Entera Health, Inc., Genentech, Inc. by F. Hoffmann-La Roche Ltd, Glaxosmithkline PLC, Merck KGaA, Neurobiologix, Inc., Novartis AG, Pfizer Inc., Progurt Inc., Samsung Biologics by Samsung Electronics Co., Ltd., SERO AS, TECHNOPATH Distribution Ltd. by Diploma PLC, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Immunoprotein Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM, Immunofixation, Prealbumin, and Protein Electrophoresis.
• Based on Application, market is studied across Allergy Testing, Autoimmune Testing, Infectious Disease Testing, and Oncology & Endocrinology Testing.
• Based on End User, market is studied across Hospital & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growth in incidence & prevalence of infectious and chronic diseases
    • 5.1.1.2. Rising geriatric population across world and increase in diagnostic tests
    • 5.1.1.3. Preferences for quick and accurate disease diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. Immunoprotein tests are costly as compared to routine microbiology assays
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in immunodiagnostic instruments
    • 5.1.3.2. Effective R&D efforts to discover therapeutics against critical disease
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative testing approaches
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Immunoprotein Market, by Product

• 6.1. Introduction
• 6.2. C3
• 6.3. C4
• 6.4. Free Light Chains
• 6.5. Haptoglobin
• 6.6. IgA
• 6.7. IgE Specific
• 6.8. IgE Total
• 6.9. IgG
• 6.10. IgM
• 6.11. Immunofixation
• 6.12. Prealbumin
• 6.13. Protein Electrophoresis

7. Immunoprotein Market, by Application

• 7.1. Introduction
• 7.2. Allergy Testing
• 7.3. Autoimmune Testing
• 7.4. Infectious Disease Testing
• 7.5. Oncology & Endocrinology Testing

8. Immunoprotein Market, by End User

• 8.1. Introduction
• 8.2. Hospital & Clinics

9. Americas Immunoprotein Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Immunoprotein Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Immunoprotein Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Celltrion Healthcare Co., Ltd.
• 3. Eli Lilly and Company
• 4. Entera Health, Inc.
• 5. Genentech, Inc. by F. Hoffmann-La Roche Ltd
• 6. Glaxosmithkline PLC
• 7. Merck KGaA
• 8. Neurobiologix, Inc.
• 9. Novartis AG
• 10. Pfizer Inc.
• 11. Progurt Inc.
• 12. Samsung Biologics by Samsung Electronics Co., Ltd.
• 13. SERO AS
• 14. TECHNOPATH Distribution Ltd. by Diploma PLC
• 15. Teva Pharmaceutical Industries Ltd.